Business Description
Niagen Bioscience Inc
NAICS : 541714
SIC : 2833
ISIN : US1710774076
Total Employee Number:
117Description
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 28.66 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.23 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 6.62 | |||||
Beneish M-Score | 0.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.6 | |||||
3-Year Book Growth Rate | 35.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 14.16 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.38 | |||||
9-Day RSI | 37.72 | |||||
14-Day RSI | 39.89 | |||||
3-1 Month Momentum % | -15.34 | |||||
6-1 Month Momentum % | -30.37 | |||||
12-1 Month Momentum % | -64.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.5 | |||||
Quick Ratio | 5.13 | |||||
Cash Ratio | 4.43 | |||||
Days Inventory | 155.41 | |||||
Days Sales Outstanding | 28.02 | |||||
Days Payable | 94.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | 2.28 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.24 | |||||
Operating Margin % | 6.67 | |||||
Net Margin % | 12.39 | |||||
EBITDA Margin % | 7.96 | |||||
FCF Margin % | 4.38 | |||||
OCF Margin % | 4.6 | |||||
ROE % | 21.25 | |||||
ROA % | 15.47 | |||||
ROIC % | 40.63 | |||||
3-Year ROIIC % | 496.74 | |||||
ROC (Joel Greenblatt) % | 55.39 | |||||
ROCE % | 10.4 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.94 | |||||
Forward PE Ratio | 23.33 | |||||
PE Ratio without NRI | 24.02 | |||||
Price-to-Owner-Earnings | 48.41 | |||||
PS Ratio | 2 | |||||
PB Ratio | 3.05 | |||||
Price-to-Tangible-Book | 3.25 | |||||
Price-to-Free-Cash-Flow | 45.52 | |||||
Price-to-Operating-Cash-Flow | 42.96 | |||||
EV-to-EBIT | 20.54 | |||||
EV-to-EBITDA | 17.22 | |||||
EV-to-Forward-EBITDA | 20.81 | |||||
EV-to-Revenue | 1.37 | |||||
EV-to-Forward-Revenue | 1.33 | |||||
EV-to-FCF | 31.18 | |||||
Price-to-GF-Value | 0.62 | |||||
Price-to-Projected-FCF | 5.53 | |||||
Price-to-Median-PS-Value | 0.4 | |||||
Price-to-Graham-Number | 1.86 | |||||
| Price-to-Net-Current-Asset-Value | 3.42 | |||||
| Price-to-Net-Cash | 5.91 | |||||
Earnings Yield (Greenblatt) % | 4.87 | |||||
FCF Yield % | 2.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Niagen Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 110.933 | ||
| EPS (TTM) (€) | 0.156 | ||
| Beta | 1.0575 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.58 | ||
| Volatility % | 32.64 | ||
| 14-Day RSI | 39.89 | ||
| 14-Day ATR (€) | 0.157902 | ||
| 20-Day SMA (€) | 2.846 | ||
| 12-1 Month Momentum % | -64.31 | ||
| 52-Week Range (€) | 2.5 - 8.7 | ||
| Shares Outstanding (Mil) | 79.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Niagen Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Niagen Bioscience Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 86 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 85 days | ||
| Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference | 2026-08-11 14:00 | In 1 day | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 16:30 | 3.06 (+5.52%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 3.06 (+5.52%) | ||
| KCSA Strategic Communications | 2026-07-15 08:00 | 2.86 (-4.67%) | ||
| General meeting for 2026 | 2026-06-24 15:00 | 2.94 (+0.68%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 16:30 | 4.10 (-0.49%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 4.10 (-0.49%) | ||
| 38th Annual ROTH Conference | 2026-03-23 17:00 | 4.02 (-0.50%) |
Show
Entries
Niagen Bioscience Inc Frequently Asked Questions
What is Niagen Bioscience Inc(STU:OCD1)'s stock price today?
The current price of STU:OCD1 is €2.60. The 52 week high of STU:OCD1 is €8.70 and 52 week low is €2.50.
When is next earnings date of Niagen Bioscience Inc(STU:OCD1)?
The next earnings date of Niagen Bioscience Inc(STU:OCD1) is 2026-11-04 Est..
Does Niagen Bioscience Inc(STU:OCD1) pay dividends? If so, how much?
Niagen Bioscience Inc(STU:OCD1) does not pay dividend.
Press Release
Articles on Niagen Bioscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers